Koordinierungszentrum für Klinische Studien der Philipps-Universität Marburg

Publikationen 2016

Kurzeder, C., Bover, I., Marme, F., Rau, J., Pautier, P., Colombo, N., Lorusso, D., Ottevanger, P., Bjurberg, M., Marth, C., Barretina-Ginesta, P., Vergote, I., Floquet, A., Del Campo, J. M., Mahner, S., Bastiere-Truchot, L., Martin, N., Oestergaard, M. Z., Kiermaier, A., Schade-Brittinger, C., Polleis, S., Du Bois, A. and Gonzalez-Martin, A. (2016). Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). Journal of clinical oncology, 34, 2516-2525.

Gonzalez-Martin, A., Pautier, P., Mahner, S., Rau, J., Colombo, N., Ottevanger, P., Del Campo, J. M., Selle, F., Du Bois, A., Gadducci, A., Garcia, Y., Berton-Rigaud, D., Marme, F., Ortega, E., Martin, N., Bastiere-Truchot, L., Kiermaier, A. and Kurzeder, C. (2016). Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer Safety Run-in Results of the PENELOPE Trial. International Journal of Gynecological Cancer 26, 898-905. 

Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M del Campo, Petronella Ottevanger, Martin Heubner, Thomas Minarik, Emmanuel Sevin, Nikolaus de Gregorio, Mariusz Bidziński, Jacobus Pfisterer, Susanne Malander, Felix Hilpert, Mansoor R Mirza, Giovanni Scambia, Werner Meier, Maria O Nicoletto, Line Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter, on behalf of the AGO Study Group led Gynecologic Cancer Intergroup (GCIG)/ European Network of Gynaecologic Oncology Trials Groups (ENGOT) Intergroup ConsortiumMDt, Prof Giovanni Scambia, MDu, Prof Werner Meier, MDv. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17: 78–89

Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, McCormack M, Plante M, Casado A, Reuss A, Chávez-Blanco A, Kitchener H, Nam BH, Jhingran A, Temkin S, Mileshkin L, Berns E, Scholl S, Doll C, Abu-Rustum. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Int J Gynecol Cancer. 2016 Jan;26(1):199-207

Maria Kleinstäuber, Japhia Gottschalk, Matthias Berking, Jörn Rau, Winfried Rief. Enriching Cognitive Behavior Therapy with Emotion Regulation Training for Patients with Multiple Medically Unexplained Symptoms (ENCERT): Design and implementation of a multicenter, randomized, active-controlled trial. Contemporary Clinical Trials 47 (2016) 54–63

Teymoortash A, Pfestroff A, Wittig A, Franke N, Hoch S, Harnisch S, Schade-Brittinger C, Hoeffken H, Engenhart-Cabillic R, Brugger M, Strauch K. Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial. PLoS One. 2016 Mar 18;11(3)

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.: Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecol Oncol. 2016 Mar;140(3):450-6.

Mengel D, Dams J, Ziemek J, Becker J, Balzer-Geldsetzer M, Hilker R, Baudrexel S, Kalbe E, Schmidt N, Witt K, Liepelt-Scarfone I, Gräber S, Petrelli A, Neuser P, Schulte C, Linse K, Storch A, Wittchen HU, Riedel O, Mollenhauer B, Ebentheuer J, Trenkwalder C, Klockgether T, Spottke A, Wüllner U, Schulz JB, Reetz K, Heber IA, Ramirez A, Dodel R. Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism Relat Disord. 2016 Aug; 29:112–116.

M. Klar, A. Hasenburg, M. Hasanov, F. Hilpert, W. Meier, J. Pfisterer, E. Pujade-Lauraine, J. Herrstedt, A. Reuss, A. du Bois: Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer 2016 Oct; 66:114-124.

Jacek P. Grabowski,  Philipp Harter, Florian Heitz, Eric Pujade-Lauraine, Alexander Reuss, Gunnar Kristensen, Isabelle Ray-Coquard, Julia Heitz, Alexander Traut, Jacobus Pfisterer, Andreas du Bois: Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecologic Oncology 2016 Mar; 140(3):457–462

Eulenburg, C., Suling, A., Neuser, P., Reuss, A., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Woelber, L. & Mahner, S. 2016. Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer. PLoS One, 11(11);

Harter, P., Sehouli, J., Reuss, A., Baumann, K., Hanker, L., Kimmig, R., Schroder, W., Burges, A., Gropp-Meier, M., Kurzeder, C., Mahner, S., Canzler, U., Luck, H. J., Meier, W., Fehm, T. & Du Bois, A. 2016. Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7). Int J Gynecol Cancer, 26(9), 1636-1641.

Woelber, L., Griebel, L.-F., Eulenburg, C., Sehouli, J., Jueckstock, J., Hilpert, F., De Gregorio, N., Hasenburg, A., Ignatov, A., Hillemanns, P., Fuerst, S., Strauss, H.-G., Baumann, K. H., Thiel, F. C., Mustea, A., Meier, W., Harter, P., Wimberger, P., Hanker, L. C., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Richter, B., Neuser, P. & Mahner, S. 2016. Role of tumour-free margin distance for loco-regional control in vulvar cancer—a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. European Journal of Cancer, 69;180-188.